[ad_1]
Clearly, biomedical innovation is accelerating at great speed and is the result of the continued development of several modes of precision medicine fueled by the genomic revolution.
Sassover continued, “Solid tumor and hematologic microenvironments are increasingly resistant to treatment and DNA mediation is essential to reactivate and restore epigenetic balance to produce favorable gene expression in the epigenomic domain. “
But despite the many advances made in oncology, cancer remains the leading cause of death in United States among those 80 and under, and the second leading cause of death worldwide.
In the United States, we lose 1,700 people a day in all age groups to cancer and those numbers are unfathomable in the context of ever-changing medical discoveries in the landscape of various innovations in the health sciences.
Nathan Sassover continues: “The World Cancer Institute has seen the disconnect in the pursuit of global medical discoveries in the parallel universe of the global escalation of human cancer in all sectors of the population, accompanied by a stratospheric acceleration. of cancer treatment costs, paradoxically combined with a continued increase in cancer. Daily reports trumpet the cost of new cancer drugs that even doctors now oppose … even when they were involved in their development. “
Meeting the cancer challenge effectively is a race against time. Most cancers are not detected until too late because there is no early detection available today for the majority of fatal cancers. We know that the earlier cancer is caught, the better the chances of a cure or success with treatment. But cancer is chaotically elusive, and often spreads and grows before symptoms appear, meaning many cancers go undetected until they have progressed to much more dreadful later stages.
Statistically, survival drops significantly at these later stages, making early detection critical in efforts to have major clinical and economic impact against cancer.
As a specific illustration, people diagnosed with lung cancer while the tumor is still localized in the lungs have a 56% chance of surviving for five years. Once the cancer has spread to other areas of the body, that number drops dramatically to just 5 percent.
Today, screening recommended by U.S. guidelines only exists for four types of cancer, leaving many deadly cancer types undetected until it is often too late for effective treatment. In addition, these screening options often face adoption issues due to risk issues related to inconvenience of invasiveness, cost, and difficult access.
As a continuing example, less than 5% of people recommended for lung cancer screening are actually screened, and many of these detected cancers occur in people who are not recommended for screening in the first place. In these conflicting scenarios, there were also concerns that the recommended screening guidelines could lead to overdiagnosis and overtreatment of cancers that can grow slowly, those that, if left undetected, would not cause harm. serious or life-changing consequences.
We are in an unprecedented era, where the genomics revolution is bringing knowledge about cancer biology and treatment decisions and outcomes.
Thus, a great challenge in bringing these transformational advancements to patient care is driven by a need for realistic assessments of time and resources to create safe and meaningful outcomes under the joint framework of the World Cancer Institute of Onco ImmunoBiology and Therapeutics.
Since its inception, the World Cancer Institute has focused on the characteristics of nascent molecular / cellular aberrations – the central genesis of cancer defined in the convergence of DNA methylation disorders and abnormalities in histone regulation that we consider the systemic onset of all types of cancer. pathology in its most premonitory but subtle form of gene expression and corresponding gene suppression.
Continued advancements are evident in cancer methylation-based diagnostic technology which analyzes DNA methylation patterns from informative regions of the genome not only to detect the presence of a cancer signal, but also to identify the “geography” of where the cancer is located in the body.
The World Cancer Institute considers that the landscape of clinical challenges and the elusive and pernicious mechanisms characteristic of cancer within the 6 most common solid tumors and 4 hematologic cancers present multiple opportunities for manifesting global unity in diagnostics and therapy. .. but also a more deliberate global commitment to early detection and proactive prevention.
SOURCE World Cancer Institute Inc.
Source link
